The Mayo SPORE in Brain Cancer comprises four investigator-initiated and led research projects, and four core resources constructed around a theme of malignant gliomas of adults. The Administrative Core provides a common management structure for the SPORE. This Core contributes to the overall efficiency of the SPORE and at the same time allows for economy of scale in its administrative and fiscal management. This in turn, frees investigators to concentrate on the science of the SPORE. The Administrative Core will support SPORE activities by providing: (1) Leadership, organizational support, and financial management for SPORE Investigators; (2) Coordination of monthly scientific meetings of SPORE investigators, and the ongoing scientific review of SPORE research projects and cores; (3) Information transfer to the scientific community via professional and public means; (4) Provision of common services for projects and cores such as administrative processing of reviews and funding statements, financial administration of grant funds, processing of IRB protocols and assurance of compliance with all NIH and Institutional grant regulations; (5) Coordination of the Internal and External Advisory Boards; (6) Oversight and management of the Developmental Research portfolio (Career Development Award; Developmental Research Award) of the SPORE; and, (7) Enhancement of communication between SPORE Investigators. The Administrative Core will foster Intra-SPORE, inter-SPORE, and intra-institutional collaborations; and, act as liaison with leadership of the other Brain SPOREs and the NCI SPORE Program.

Public Health Relevance

Compared to other more common cancers malignant gliomas are responsible for a disproportionate amount of morbidity and mortality because of their disabling impact on cognition, memory, language, mobility, and adaptive skills. In addition to significant reduction in life expectancy each new case impacts the nation's public health since its morbidity represents on average twenty years of lost productivity. Whether the payer is public or private, diagnosis and treatment, including supportive care in the terminal stages of disease, extracts enormous health care expenditures.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA108961-07
Application #
8555426
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Project Start
2004-09-20
Project End
2016-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
7
Fiscal Year
2012
Total Cost
$60,114
Indirect Cost
$26,910
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Hardcastle, Jayson; Mills, Lisa; Malo, Courtney S et al. (2017) Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol 19:493-502
Robinson, Steven; Galanis, Evanthia (2017) Potential and clinical translation of oncolytic measles viruses. Expert Opin Biol Ther 17:353-363
Kurokawa, C; Geekiyanage, H; Allen, C et al. (2017) Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma. J Neurooncol 131:41-48
Kizilbash, Sani H; Gupta, Shiv K; Chang, Kenneth et al. (2017) Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther 16:2735-2746
Melin, Beatrice S; Barnholtz-Sloan, Jill S; Wrensch, Margaret R et al. (2017) Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet 49:789-794
Yin, Xueqian; Kang, Jeong-Han; Andrianifahanana, Mahefatiana et al. (2017) Basolateral delivery of the type I transforming growth factor beta receptor is mediated by a dominant-acting cytoplasmic motif. Mol Biol Cell 28:2701-2711
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2017) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets :
Heim, Joel B; Squirewell, Edwin J; Neu, Ancilla et al. (2017) Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix. Proc Natl Acad Sci U S A 114:3933-3938
Tivnan, Amanda; Heilinger, Tatjana; Ramsey, Joanne M et al. (2017) Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. Oncotarget 8:16605-16620
Pekmezci, Melike; Rice, Terri; Molinaro, Annette M et al. (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001-1016

Showing the most recent 10 out of 243 publications